Biotech Startups

A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.

1 investor

OMTX develops machine learning tools and datasets for drug discovery, helping researchers globally identify new therapeutic mechanisms of action and accelerate the development of medicines.

1 investor

Omanta provides personalized scientific research support for complex disease cases, assigning PhD-level teams to build detailed molecular profiles from a patient's genomic, RNA, and protein data. It cross-references each patient's molecular profile against an internal reference cohort and biomedical literature to model therapeutic options and produce a research roadmap that informs the clinical team's decisions.</parameter> <parameter name="founders">[]

1 investor

Omeat (Evergreen) produces cultivated beef that augments traditional beef supply to deliver price-predictable, consistent-quality product at industrial scale. It partners with ranchers, global meat producers, and beef processors seeking stable pricing and reliable supply without plant-based fillers.

1 investor

Omerna Biosolutions develops a dsRNA-based anti-fungal crop protection product that is targeted, non-GMO, and non-toxic, and can be combined with traditional fungicides to control fungal pathogens and extend shelf life. The company serves agriculture, targeting crop loss from fungal pathogens, and is based on technology from the Volcani and Weizmann Institutes in Israel.

1 investor

OmniActive develops scientifically validated, nature-based ingredients for the nutraceutical and natural products industry. The company specializes in extracting and delivering innovative ingredient solutions sourced from spices and natural materials.

1 investor

OmniBio develops biologically-inspired AI models for autonomous robots and machines used in manufacturing, agriculture, and construction. The technology enables robots to learn and adapt in dynamic environments without traditional sensors or connectivity.

1 investor

Omnicare is a German healthcare group focused on oncology, operating medical care centers (MVZ) with physicians and oncologists across multiple sites, clean-room laboratories, pharmaceutical wholesale, hygiene monitoring, and quality initiatives for pharmacies and oncology practices. It also runs psychosomatic clinics and provides software (eApo) and training for medical staff.

1 investor

OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.

1 investor

1 investor

Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.

1 investor

1 investor

OmniPulse Bio develops next-generation therapies described as pulsatile and programmable. The page provides no concrete detail about the therapeutic area, product, or intended patients.

1 investor

Omniscience.bio builds Vivo, an agentic AI "control tower" that unifies data from clinical trial systems (EDC, CTMS, labs, safety, imaging, eCOA, IRT, documents) into a governed layer where teams ask plain-language questions, monitor risk, and take source-backed action. It serves cross-functional clinical development teams, sponsors, and CRO/FSP partners running active trials, in the clinical trial software and life sciences category.

1 investor

Omniscope develops diagnostics and therapeutics technology based on the convergence of AI and immunology, aiming to interpret immune system data to generate therapeutics, develop diagnostics, and monitor patients. Founded in 2020, the company applies machine learning to immunology with a focus on health equity.

1 investor

Omos Biosciences develops molecular diagnostic tools that analyze the molecular signatures of pre-cancers to identify which cases are high risk and require intervention. The technology is aimed at helping clinicians with treatment stratification to reduce over-treatment and enable early cancer intervention.

1 investor

Order-made Medical Research Inc. (OMR) develops antibody drug discovery technologies, including its LIMAXYS platform for generating antibodies against multi-pass transmembrane targets, plus the INTAB and MUTAB platforms for internalizing and disease-specific mutation antibodies. The company aims to create new antibody-based therapies for hard-to-treat cancers, autoimmune diseases, and neurodegenerative disorders.

1 investor

Onava is a drug discovery company that combines AI-native protein engineering, autonomous orchestration of model training and experimental feedback, and high-throughput functional assays to develop next-generation therapeutics. Its platform uses a cross-program data flywheel where insights from each program inform future candidate optimization.

1 investor

Onc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.

1 investor

Onchilles Pharma is a biopharmaceutical company developing novel therapeutics based on scientific research to address unmet medical needs. The company is led by a team with academic and industry backgrounds in drug development.

1 investor

Oncobit provides molecular diagnostic solutions that enable clinicians to monitor cancer and optimize therapy selection through advanced genetic analysis of plasma samples.

1 investor

Oncoclínicas operates a network of over 140 units — clinics, genomics and pathology laboratories, and integrated cancer treatment centers — across 40 Brazilian cities. It provides cancer diagnosis and treatment services for patients in Brazil.

1 investor

Oncodea is a cancer research company developing early cancer detection and monitoring methods intended to be fast, affordable, and accessible to a broad population. It positions itself as more than a research lab, focused on making cancer testing inexpensive enough for regular use.

1 investor

OncoForma develops a functional precision oncology platform that tests patient-derived tumor organoids against comprehensive drug panels to predict treatment efficacy before therapy begins. The company serves oncologists and cancer patients in the global oncology market, operating from Saskatchewan with a pathway to scale from fee-for-service testing to AI-enabled predictive medicine.

1 investor